Navigation Links
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Date:11/23/2009

THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

The GASTRO 2009 meeting is a joint world conference in the area of gastroenterology. This meeting will bring together the world's leading organizations - the United European Gastroenterology Federation (UEGF), World Gastroenterology Organization (WGO), World Organization of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG) - for one of the biggest congresses in this area of medicine with more than 12,000 scientists from around the world expected to attend.

A summary of the GASTRO 2009 presentation (with audio) will be available on Lexicon's corporate website at www.lexpharma.com on November 25, 2009.

About LX1031

LX1031 is an orally available, locally acting inhibitor of tryptophan hydroxylase (TPH), an enzyme necessary for the biosynthesis of serotonin. LX1031 acts by selectively decreasing the production of serotonin in the gastrointestinal tract. Discovered and developed by Lexicon, LX1031 is the first TPH inhibitor ever to be evaluated in human clinical trials for the treatment of IBS. In Phase 1 clinical trials, all dose levels of the drug were well tolerated, and no dose-limiting toxicities were observed. LX1031 was also shown to reduce levels of urinary 5-HIAA, a biomarker of serotonin production.

LX1031 is being developed in collaboration with Symphony Capital LLC.

About Irritable Bowel Syndrome

Irritable bowel syndrome is a disorder most commonly characterized by cramping, abdominal pain, bloating, constipation or diarrhea. According to the International Foundation for Functional Gastrointestinal Disorders, IBS affects between 25 and 45 million people in the United States. Symptoms of IBS are believed to be mediated through serotonin, which has been shown to play an important role in modulating motility and signaling feelings of GI discomfort.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's plans for further clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products other than LX1031, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to the clinical development of LX1031 and preclinical and clinical development of Lexicon's other potential drug candidates and Lexicon's ability to successfully advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
2. Lexicon Announces Completion of Public Offering of Common Stock
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
5. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Indiso ltd , a medical technology company ... respiratory diseases announced today positive results in its clinical ... patients show improvements in respiratory functions and other clinical ... Upper and lower respiratory tract diseases and allergy ... reached epidemic level. Increasing number of studies however show ...
(Date:2/10/2016)... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has ... Diagnostics Reports Bundle" report to their ... announced the addition of the "Molecular ... offering. --> Research and Markets ... of the "Molecular Diagnostics Reports Bundle" ...
(Date:2/10/2016)...  Cepheid (Nasdaq: CPHD ) today announced ... President and Chief Operating Officer, has been promoted ... Officer.  In his new capacity, Mr. Kocmond,s responsibilities ... Operations in addition to Manufacturing Operations, Engineering, Technical ... to report to John Bishop , Cepheid,s ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s Dream ... $10,000 to University of Chicago to support ovarian cancer research being conducted by Dr. ... to support a promising young investigator from Dr. Lengyel’s lab at the University of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly ... for a series of therapeutic sessions to help Los Angeles-area actors cope with ... their lives. The series, known as “Mindfulness for Actors and Artists,” has been ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
Breaking Medicine News(10 mins):